Contact the Editorial Desk

Editorial correspondence

The casebook welcomes notes on the record itself: a citation quoted loosely, a newly published case report or trial on GLOW's constituents or on Melanotan II, or a regulatory update that shifts an approval or prohibited-substance status. That is the most valuable mail this file receives, and each note is read with care.

The notes easiest to act on name the page in question, the exact passage being corrected or challenged, and a supporting reference — a DOI or PubMed identifier wherever you have one — so a proposed change can be checked against its source before an entry is touched.

Editorial mailbox: editors@peptiderejuvination.com

Outside the casebook's remit

Because Peptide Rejuvination reads and records the literature rather than practicing dermatology, cosmetics, or medicine, it cannot: advise on or endorse human use of GLOW, Melanotan II, or any of their constituents; name a dose, schedule, or route for any individual; judge whether a cited finding fits a specific person's skin, health, or situation; or sell, source, suggest, or help locate a supplier for any compound. And since TB-500 sits on WADA's Prohibited List, the casebook can't counsel athletes under anti-doping testing on using GLOW either.

Anyone seeking clinical or dermatological guidance should consult a licensed provider in their jurisdiction. Replies aren't guaranteed and can lag; the mailbox is checked now and then.